IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.628
EU - Europa 9.729
AS - Asia 8.324
SA - Sud America 1.562
AF - Africa 653
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 18
Totale 39.942
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.684
SG - Singapore 4.389
CN - Cina 2.927
IE - Irlanda 2.644
IT - Italia 2.442
UA - Ucraina 2.386
BR - Brasile 1.430
CA - Canada 861
RU - Federazione Russa 685
CI - Costa d'Avorio 405
DE - Germania 313
SE - Svezia 309
IN - India 242
GB - Regno Unito 230
KR - Corea 146
VN - Vietnam 143
SN - Senegal 138
FR - Francia 105
FI - Finlandia 104
CH - Svizzera 86
NL - Olanda 82
UZ - Uzbekistan 73
PL - Polonia 64
AT - Austria 61
BD - Bangladesh 60
CZ - Repubblica Ceca 49
JP - Giappone 47
MX - Messico 47
BE - Belgio 44
GR - Grecia 43
AR - Argentina 42
TR - Turchia 40
IQ - Iraq 38
ZA - Sudafrica 37
LB - Libano 35
HK - Hong Kong 29
ES - Italia 24
MA - Marocco 24
EC - Ecuador 22
AU - Australia 20
VE - Venezuela 20
EU - Europa 18
IR - Iran 18
PK - Pakistan 18
IL - Israele 17
JO - Giordania 14
CO - Colombia 13
SA - Arabia Saudita 12
AE - Emirati Arabi Uniti 11
NG - Nigeria 11
AZ - Azerbaigian 10
BG - Bulgaria 10
BO - Bolivia 10
KE - Kenya 10
NO - Norvegia 9
PY - Paraguay 9
DZ - Algeria 8
KZ - Kazakistan 8
LT - Lituania 8
RS - Serbia 8
TN - Tunisia 8
CL - Cile 7
DO - Repubblica Dominicana 7
EG - Egitto 7
NZ - Nuova Zelanda 7
JM - Giamaica 6
RO - Romania 6
BH - Bahrain 5
KW - Kuwait 5
NP - Nepal 5
PE - Perù 5
PS - Palestinian Territory 5
BB - Barbados 4
CR - Costa Rica 4
PH - Filippine 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
HN - Honduras 3
LU - Lussemburgo 3
MY - Malesia 3
OM - Oman 3
PT - Portogallo 3
SI - Slovenia 3
UY - Uruguay 3
AL - Albania 2
AM - Armenia 2
AO - Angola 2
HU - Ungheria 2
ID - Indonesia 2
KG - Kirghizistan 2
LK - Sri Lanka 2
PA - Panama 2
SV - El Salvador 2
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GL - Groenlandia 1
Totale 39.931
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.876
Singapore 2.684
Jacksonville 2.636
Dublin 2.627
Chandler 2.134
Boardman 1.117
Chicago 948
Catania 877
Nanjing 751
Cambridge 720
Andover 716
Lawrence 715
Toronto 644
Ashburn 534
Houston 496
Des Moines 423
Abidjan 403
San Mateo 386
Hefei 358
Beijing 275
Nanchang 262
Wilmington 261
Civitanova Marche 229
Saint Petersburg 182
Shenyang 180
Hebei 176
Ottawa 148
Jiaxing 147
Seoul 146
Dakar 138
Los Angeles 135
Changsha 134
Florence 131
São Paulo 113
Tianjin 109
Grafing 96
Council Bluffs 92
Kochi 92
Rome 90
Dong Ket 87
Munich 71
New York 69
Milan 65
Moscow 61
Seattle 59
Palermo 57
Washington 57
Brooklyn 55
The Dalles 51
Columbus 46
San Francisco 45
Hangzhou 43
Boston 42
Turku 42
Brussels 41
Den Haag 39
Helsinki 38
Rio de Janeiro 38
Norwalk 37
Tokyo 37
Belo Horizonte 35
Kunming 35
Falls Church 32
Pune 31
Hanoi 29
Jinan 29
Stockholm 29
Bremen 28
Montreal 27
Warsaw 27
Hong Kong 26
Guangzhou 25
Phoenix 25
Mumbai 24
Tashkent 24
Johannesburg 23
Lappeenranta 23
Bari 22
Brno 22
Messina 22
Porto Alegre 22
Ann Arbor 20
Dallas 20
Liberty Lake 20
Atlanta 19
Chennai 19
Brasília 18
Campinas 18
Frankfurt Am Main 18
Mexico City 18
Redwood City 18
Zhengzhou 18
London 17
Hanover 16
Ningbo 16
Fortaleza 15
Naples 15
San Jose 15
Augusta 14
Curitiba 14
Totale 27.149
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 236
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 221
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 170
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 165
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 157
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 142
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 127
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 118
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 117
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 114
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 110
Il Rasario. Semeiotica medica 104
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 103
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 100
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 99
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 98
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 95
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 95
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 94
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 94
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 94
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 94
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 94
Terapia del mieloma multiplo 93
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 93
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 93
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 92
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 92
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 92
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 91
Hedgehog signaling pathways in multiple myeloma 89
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 89
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 89
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 89
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 89
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 89
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 88
A snapshot of asparaginase-induced liver insufficiency. 86
Acute pre-hepatic portal thrombosis: diagnosis and therapy 86
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 86
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 86
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 86
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 85
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 85
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 84
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 83
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 83
Cementoplasty in the management of painful extraspinal bone metastases: our experience 83
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 83
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 83
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 82
Lymphoma of the cecum: a case report 81
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 81
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 81
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 81
Eventi avversi e trigger C12: Stroke in ospedale 81
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 81
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 80
Uncommon long-term survival in a patient with chronic myeloid leukemia 80
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 80
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 80
Bone turnover markers in patients with type 1 Gaucher disease 80
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 79
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 79
Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile 79
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 78
Angiogenesis in acute myeloid leukemia 78
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 78
Vg9Vd2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells 78
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 78
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 78
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 78
Effects of imatinib mesylate in osteoblastogenesis 77
Chitotriosidase Expression during Monocyte-Derived Dendritic Cells Differentiation and Maturation 77
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 77
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. 77
Clinical and Endoscopic Presentation of Primary Gastric Lymphoma: An Italian Multicenter Study 77
Emangioma, plasmocitoma e mieloma multiplo del rachide 77
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 77
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 76
Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML 76
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 76
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 76
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 76
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 75
SMOLDERING MYELOMA: WALKING THROUGH RISK FACTORS AND TENTATIVE CLASSIFICATION SYSTEMS 75
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 75
NEUTROPHIL TO LYMPHOCYTE RATIO IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 75
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 75
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 75
Detection of fungal dna in lysis-centrifugation blood culture for the prevision of response to antifungal in aml patients with persistent neutropenic fever: a pilot subset 74
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 74
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 74
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients 73
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 73
PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS 73
Rate of fungal infections in patients with acute myeloid leukemia during induction treatment performing two prophylactic strategies: preliminary results 73
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 73
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 73
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 73
Totale 9.061
Salva come PNG Salva come JPEG
Categoria #
all - tutte 167.406
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 167.406
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.908 0 382 564 81 1.175 67 540 13 470 8 430 178
2021/20225.171 637 763 22 43 872 42 762 175 524 28 122 1.181
2022/20237.429 743 273 104 503 714 1.384 24 1.266 1.976 58 274 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.800 99 2.090 837 448 2.795 1.044 380 521 1.091 1.399 960 1.136
2025/20262.082 1.673 409 0 0 0 0 0 0 0 0 0 0
Totale 40.998